NNEPQIN Winter Meeting
January 20, 2014
Auditoria E & F, Dartmouth-Hitchcock Medical Center, Lebanon, NH
SCOPE of Pain: Safe and Competent Opioid Prescribing Education
The Background: What is SCOPE of Pain?
SCOPE of Pain is designed to help you safely and effectively manage patients with chronic pain, when appropriate, with
opioid analgesics. The FDA has mandated manufacturers of extended release/long-acting (ER/LA) opioid analgesics, as part
of a comprehensive Risk Evaluation and Mitigation Strategy (REMS), to make available comprehensive prescriber education
in the safe use of these medications. Our training is based on the FDA curriculum known as the Blueprint for Prescriber
Education for Extended Release and Long-Acting Opioid (ER/LA) Analgesics. Our curriculum covers all aspects of this
blueprint and more to provide a comprehensive educational program.
Target Audience: Obstetricians, Midwives, Family Physicians, Pediatricians, Nurses & Addiction Specialists
8:45
Welcoming Remarks & Overview of Prescribing Habits
Michele R. Lauria, MD, MS, Professor OB/GYN & Radiology
Dartmouth-Hitchcock Medical Center & Medical Director, NNEPQIN
9:00
Assessing Chronic Pain and Opioid Misuse Risk (** See Funding Note Below)
Objectives:
 Discuss prevalence of chronic pain in the US
 Discuss prevalence of the use and misuse of opioid analgesics
 Describe the pharmacology, efficacy and safety of opioid analgesics
 Describe the components of a thorough opioid misuse risk assessment for a
potential candidate for chronic opioid therapy
Jane Liebschutz, MD, MPH
Associate Professor of Medicine and Social and Behavioral Sciences
Boston University Schools of Medicine and Public Health and Boston Medical Center, Boston, MA
10:00
Initiating Opioid Therapy Safely (**See Funding Note Below)
Objectives:
 Describe universal precautions and their role in chronic opioid therapy
 Describe monitoring and documentation strategies for chronic opioid therapy
 Describe initiating opioid therapy
 Apply counseling and communication strategies to ensure appropriate and safe use of opioid
medications
Seddon R. Savage MD, MS
Medical Director, Chronic Pain and Addiction Center, Silver Hill Hospital
Director, Dartmouth Center on Addiction Recovery & Education, Geisel School of Medicine at Dartmouth
11:00
Break
11:15
NNEPQIN Guideline for the Peripartum Management of Opioid Tolerant Patients
Objectives:
 Identify aspects of the guideline that require revision prior to implementation in practice
 Discuss guideline implementation strategies and opportunities to track effectiveness
Jerome Schlachter, MD
Obstetrics & Gynecology, Dartmouth-Hitchcock Manchester, Manchester, NH
12:00
Lunch
1:00
Assessing and Managing Aberrant Medication Taking Behavior (**See Funding Note Below)
Objectives:
 Assess differential diagnosis for aberrant medication taking behavior
 Assess lack of benefit, increased risk and/or harm
 Determine whether to continue, change or discontinue opioid therapy
 If changing opioids, determine how to rotate opioids
 If discontinuing opioids, determine whether and how to taper opioids
Jane Liebschutz, MD, MPH
Associate Professor of Medicine and Social and Behavioral Sciences
Boston University Schools of Medicine and Public Health and Boston Medical Center, Boston, MA
2:00
Multi-Dimensional Care of Chronic Pain
Objective: Discuss strategies to reduce reliance on opioids for pain relief
Seddon R. Savage MD, MS
3:00
Implementing a Medication Drop Box in your Community
Objectives:
 Describe the regulations regarding medication drop box placement
 Promote cooperation between your hospital and your local police department to identify
resources to support a local medication drop box
Police Chief Kenneth J. Meola
Keene Police Department, Keene, NH
4:15
Evaluation and Wrap-Up
Register Now! Click HERE
Registration Fee: NNEPQIN Member Organizations: No Charge
Questions? Email us: info@nnepqin.org
Non NNEPQIN Organizations: $100.
Continuing Education Accreditation
CME: Boston University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical
education for physicians.
Boston University School of Medicine designates this live activity for a maximum of 6.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only
the credit commensurate with the extent of their participation in the activity.
NURSING: Continuing Nursing Education Provider Unit, Boston University School of Medicine is accredited as a provider of continuing nursing
education by the American Nurses Credentialing Center's Commission on Accreditation.
Contact Hours: 6.25
These activities are sponsored by Boston University School of Medicine and co-sponsored by Dartmouth-Hitchcock Medical Center. Boston University
School of Medicine’s national collaborators are the Council of Medical Specialty Societies (CMSS) and the Federation of State Medical Boards (FSMB).
Our program addresses many key elements of the physician education component of the Obama Administration's prescription drug abuse prevention
plan on prescriber education released in April 2011.
Course Director: Daniel P. Alford, MD, MPH, FACP, FASAM, Boston University School of Medicine
AAFP (American Academy of Family Physicians): This enduring material activity, SCOPE of Pain: Safe and Competent Opioid Prescribing Education, has
been reviewed and is acceptable for up to 3 Prescribed credits by the American Academy of Family Physicians. AAFP certification begins March 1,
2013. Term of approval is for one year from this date with the option of yearly renewal. Physicians should claim only the credit commensurate with
the extent of their participation in the activity.
**Funding
This program is funded by an independent educational grant awarded by the manufacturers of extended-release (ER) and long-acting (LA) opioid
analgesics, collectively known as the Risk Evaluation and Mitigation Strategy (REMS) Program Companies, or RPC. This activity is intended to be fully
compliant with the ER/LA Opioid Analgesic REMS education requirements issued by the U.S. Food & Drug Administration (FDA).